We provide professional support in Regenerative Medicine & Stem Cell.
Our Unit aims to provide stem cell / bone marrow
transplantation services at a world-class standard to all our patients from
around the world; Yeditepe University Hospital’s stem cell unit is a member of
the American Association of Blood Banks (AABB), the International Society for
Cellular Therapy (ISCT) and the American Society for Bone Marrow
Transplantation. Our stem cell transplantation team was recognized as a
European transplantation center on 9th February 2006 when it was listed
on the European Bone Marrow Transplantation Registry. ON 5th April
2006 the unit gained accreditation for non-relative stem cell transplantations,
meaning we can carry out bone marrow transplantations from stem cells procured
with hematologic cancers, non-malignant blood diseases and solid tumors may be
admitted to our stem cell transplantation program. The following diseases are
currently treated by means of stem cell transplantation:
Blood Cancer (Leukemia)
Lymph Node Cancer (Lymphoma)
Aplastic anemia (bone marrow failure)
Mediterranean Anemia (Thalassemia)
Kidney Cancer (Renal Cancer)
Severe immunodeficiency (Immuno-deficiencies)
Some genetic blood diseases (thalassemia, sickle-cell anemia)
There is no need for blood compatibility in hematopoietic
stem cell transplantations. The physician will carry out the procedure having
taken the necessary precautionary measures; in this event the recipient’s blood
group will change so that he or she takes on the donor’s blood group.
SCT is a multidisciplinary method of treating
life-threatening conditions that are not responsive to conventional treatment.
If the patient is a child, the reasons for the advisability of the treatment,
how it is carried out, outcomes, and information on early and long term risks
is carefully explained verbally and in writing to the child’s legal guardians
(in most cases the child’s parents). The procedure begins only when written
consent has been obtained after this briefing.
The post-transplantation growth and developmental progress of children, their performance at school and
other natters requires special monitoring in a way that is different from adult
cases. Nowadays there is a population around the world who have already
completed a 25 to 30 year period following hematopoietic stem cell
transplantation. With the ever longer lifespan of SCT patients, their long term
monitoring involves not just medical check-ups but also issues such as
psychosocial problems and improving their quality of life.